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Background
People with bipolar disorder typically require long-term
pharmacological treatment to prevent episodes of depression or
mania. However, evidence-based guidelines are often not fol-
lowed by prescribers and, in some countries, prescribing of
lithium is in decline. Polypharmacy is also common in bipolar
disorder.
Aims
To employ a data linkage approach to describe and evaluate
prescribing patterns in bipolar disorder in Scotland between
2009 and 2016.
Method
By linking prescribing data to the electronic Scottish Morbidity
Records, we identified a cohort of 23 135 patients with bipolar
disorder who were prescribed psychotropic medication
between 2009 and 2016. We examined trends in proportions of
patients prescribed each of six drug categories. Random effects
logistic models examined change in prescribing over years of
interest.
Results
The most common form of treatment was antidepressant
monotherapy (24.96%), with only 5.90% of patients receiving
lithium monotherapy. Prescribing of antipsychotics and anti-
epileptics increased from 2009 to 2016 (antipsychotics: odds
ratio 1.16, 95% CI 1.15–1.18; anti-epileptics: odds ratio 1.34, 95%
CI 1.32–1.36), whereas prescribing of lithium decreased (odds
ratio 0.83, 95% CI 0.82–0.85). Prescribing of valproate decreased
from 2009–2016 in women, but increased in men (women:
odds ratio 0.93, 95% CI 0.90–0.97; men: odds ratio 1.11, 95% CI
1.04–1.18).
Conclusions
Antidepressant monotherapy was the most common form of
treatment for bipolar disorder in Scotland and prescribing of
lithium has declined between 2009 and 2016. The findings are
concerning and represent a gap between treatment guidelines
and clinical practice.
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Pharmacological treatment for bipolar disorder
Bipolar disorder is a severe affective disorder characterised by epi-
sodes of depression and mania or hypomania. It affects 1–2% of
the global population and is associated with a wide range of
adverse mental and physical health outcomes.1,2 Many individuals
with bipolar disorder require long-term medication to treat and
prevent episodes and to maintain mood stability.
Current pharmacological treatment options for bipolar dis-
order are broad and include mood stabilisers (e.g. lithium, sodium
valproate), antipsychotics, antidepressants, hypnotics, anxiolytics
and anti-epileptics.3 Despite the availability of newer treatments,
lithium is still considered the most effective treatment for reducing
recurrence of episodes and since 2014 has been recommended as a
first-line treatment by the National Institute of Health and Clinical
Excellence (NICE).3 Prior to this, 2006 guidelines recommended
lithium, valproate or olanzapine (an antipsychotic) as first-line
treatments.4 There is also evidence that lithium has a specific
anti-suicidal effect and it may be associated with fewer long-term
negative physical health outcomes than other psychotropic medica-
tions.5,6 Moreover, the risk to the fetus of intrauterine exposure to
lithium as well as the long-term risk of renal failure in people
treated with lithium are both lower than previously reported.7,8
Despite NICE recommendations, however, lithium remains
under-prescribed in clinical practice. Indeed, bipolar disorder has
been identified as one of the areas of psychiatry with the widest
gap between evidence-based treatment and clinical practice.9
Changes in prescribing for bipolar disorder
Routine healthcare data linkage studies in several countries have
identified important changes in the use of lithium over time.10,11
Using national-level data from Denmark, Kessing and colleagues
recently assessed prescription data for bipolar disorder between
2000 and 2011.10 Of the four drug categories studied, lithium
went from being the most common drug prescribed for bipolar dis-
order to the least common, and was replaced by the use of atypical
antipsychotics.10 Similar findings have emerged in Sweden, where
lithium prescriptions for bipolar disorder decreased from 2007 to
2013.12 In partial contrast with these studies, however, an Italian
study found that a drop in lithium prescriptions from 2002–2006
was followed by an increase from 2006–2010, perhaps reflecting
changing attitudes among health practitioners.13
There has also been an increase in polypharmacy for bipolar
disorder in many countries.14 Although combination treatments
can sometimes be indicated, ‘irrational polypharmacy’, with co-
prescription of medications that are redundant, inappropriate or
even harmful is well documented. Overall, polypharmacy is thought* These authors contributed equally to this article.
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to occur in up to 85% of people with bipolar disorder and has been
linked to increased risk of medical comorbidities.14
Aims
It is currently unclear whether prescribing changes observed in
other countries have also occurred in the UK in recent years. The
excellent routine data linkage infrastructure in Scotland facilitates
assessment of changes in patterns of prescribing for bipolar disorder
over time at a population level. Here, we used a health informatics
approach to conduct a Scottish national-level assessment of pre-
scribing patterns for bipolar disorder between 2009 and 2016.
Methods
Data sources
In Scotland, publicly funded healthcare is administered through 14
National Health Service (NHS) health boards. In each health board,
records of out-patient clinic attendance, general/acute hospital
admissions and psychiatric hospital admissions have been recorded
in Scottish Morbidity Records (SMR) since 1981. These SMR
records contain data obtained through routine clinical encounters,
including dates and duration of attendance/admission. Diagnoses
are coded using International Classification of Diseases (ICD)-9
(1981) and ICD-10 (1995). Date and primary and secondary
causes of death (ICD-9/ICD-10) have been recorded in the
National Records of Scotland (NRS) deaths register since 1981.
Since 1999, information on the date, number, strength, formulation
and quantity of prescriptions dispensed in the community in
Scotland has been recorded on a Prescribing Information System
(PIS).15 Patient date of birth and gender are included in both
SMR and PIS records, and ethnicity, marital status and Scottish
Index of Multiple Deprivation (SIMD) score are sometimes
recorded by health professionals.
In Scotland the use of a unique patient identifier, the
Community Health Index number, facilitates linkage of routine
health databases by the Information Services Division (ISD) of
NHS Scotland. The ISD provides access to linked data sets by
approved researchers via the National Services Scotland National
Safe Haven and via four regional Safe Havens located within
Aberdeen, Dundee, Edinburgh and Glasgow. These Safe Havens
provide secure access to patients’ clinical data as well as a research
platform for the collation, management, dissemination and analysis
of anonymised electronic patient records.
Working with the ISD, we used SMRs dating back to 1981 for
hospital out-patient attendance (SMR00), general/acute hospital
admission (SMR01) and psychiatric hospital admissions (SMR04)
to identify a cohort of individuals in Scotland with a diagnosis of
bipolar disorder (ICD-10 codes F30, F31, F38.0; ICD-9 codes
296.0–296.1, 296.4–296.89). All individuals in this cohort were
linked to the PIS, available from 2009–2016 at the time data were
obtained, to obtain information on the date and type of prescrip-
tions received. From the PIS, data on prescriptions for lithium, val-
proate (both classified as ‘mood stabilisers’), antipsychotics, anti-
epileptics, hypnotics, anxiolytics and antidepressants were
extracted, as these reflect the most common categories of medica-
tion prescribed in bipolar disorder.16 In the analyses below, hypno-
tics and anxiolytics were collapsed into a single category, as in the
British National Formulary chapter 4.1 ‘Hypnotics and anxioly-
tics’.17 We had a particular interest in prescribing patterns for
lithium over time (the first-line treatment according to NICE guide-
lines) so it was examined separately. Valproate was also examined
separately to ascertain any changes in its use in response to recent
guidelines relating to risks associated with fetal exposure.18
Participants
A cohort of 45 276 patients with a diagnosis of bipolar disorder as
defined by ICD codes was identified from SMR00, SMR01 and
SMR04 records. Of this cohort, 23 261 individuals, according to
the PIS, received at least one prescription of any of the drug categor-
ies of interest (hypnotics/anxiolytics, antipsychotics, lithium, val-
proate, antidepressants or anti-epileptics) between 2009 and 2016.
Of these, 126 (0.5%) had ICD codes which are typically used to
code bipolar disorder type II, or ‘other/unspecified’ bipolar disor-
ders (ICD-10 F31.8; ICD-9 296.8). For greater consistency of
bipolar types included, we excluded these patients to focus ana-
lyses on patients with ICD codes consistent with bipolar disorder
type I (n = 23 135). For the current analyses, when examining each
year of interest separately, individuals were excluded if their earli-
est SMR record of bipolar disorder was during or after the year of
interest, or if their year of death, if applicable, was during or before
the year of interest. For some analyses, we collapsed across all years
of interest: in these cases, the sample consisted of patients whose
earliest SMR record of bipolar disorder was before 2009, whose
record of death was after 2009 or not applicable and who received
relevant prescription(s) in any year from 2009–2016.
It is not possible to ascertain reliably from the SMR/PIS
data whether those individuals in the bipolar disorder cohort (iden-
tified through the SMR) who did not have any PIS records of
any prescriptions (of the selected categories) were still resident
and/or receiving treatment in Scotland for each year of interest.
Individuals without records of relevant prescriptions may have
been resident in Scotland but not receiving psychotropic medication
(in the categories of interest), or may no longer be registered with
the Scottish NHS and are either receiving treatment elsewhere or
have died elsewhere. As a result, our analyses were focused on indi-
viduals with PIS records for the major medication categories of
interest. We were unable to estimate how many individuals with
bipolar disorder in Scotland were unmedicated or receiving other
psychotropic medications.
For the majority of analyses, we applied the inclusion criterion
that an individual must have been consistently prescribed the same
medication for aminimum period of 3months in the year of interest
(see Medication variables).
Medication variables
Prescriptions were coded into six categories of medications:
hypnotics/anxiolytics (British National Formulary subsection 4.1
‘Hypnotics And Anxiolytics’), antipsychotics (British National
Formulary chapter 4.2 ‘Drugs used in psychoses and related disor-
ders’, excluding lithium and valproate), lithium (British National
Formulary subsection 4.2.3 ‘Drugs used for mania or hypomania’,
specific drug codes lithium carbonate or lithium citrate), valproate
(British National Formulary subsection 4.2.3 ‘Drugs used for
mania or hypomania’, specific drug code valproic acid; or British
National Formulary chapter 4.8 ‘Antiepileptic drugs’, specific drug
codes [semi]sodium valproate or valproic acid), antidepressants
(British National Formulary chapter 4.3 ‘Antidepressant drugs’)
or anti-epileptics (British National Formulary chapter 4.8
‘Antiepileptic drugs’, excluding [semi]sodium valproate and val-
proic acid).17
For each year of interest, individuals were coded as having been
prescribed a given drug category (from the categories listed above)
for an estimated minimum 3months if (a) they received at least four
prescriptions of the same drug category within a year, and (b) the
average interval between prescriptions was between 21 and 84
days. This interval was selected based on the estimated typical dur-
ation of chronically prescribed prescriptions of around 56 days
(between 28 and 84 days):19 an 84 day window is typically
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considered a reliable metric of drug exposure; a 21 day lower cut-off
was selected to allow for early collection of prescriptions. Coding
was not mutually exclusive: the same individual could meet the cri-
teria for more than one drug category. In the analyses below,
‘treated’ refers to patients meeting these criteria.
We also calculated individuals’ most typical form of treatment,
in the form of their modal combination of drug categories across all
years of interest. We defined combinations of drug categories as
those prescribed together on the same date, thus using a conserva-
tive definition of drug category polypharmacy. For prescriptions
meeting the above 3 month minimum criteria, each patient’s
modal combination of drug categories prescribed on the same
date was defined as their modal form of treatment. This modal com-
bination could consist of only one drug category (referred to as
‘monotherapy’, although this may comprise more than one specific
drug from the same category) or multiple types (‘polypharmacy’
here referring to prescription of more than one drug category).
The modal form of treatment was also calculated separately for
each year from 2009 to 2016. We applied the criterion that the
modal combination of drug types must make up at least one third
of the individual’s total prescriptions for a given year (distinct pre-
scriptions counted as distinct dates on which prescriptions were
received). This was to account for patients who were undergoing
a change in their treatment regimen, resulting in ‘trials’ of different
combinations. As an example, for an individual who received five
prescriptions of lithium and an antidepressant (each time pre-
scribed on the same date and meeting 3 month minimum criteria)
and four of lithium monotherapy within a year, the lithium/anti-
depressant polypharmacy would be coded as their modal drug com-
bination for that year.
Demographic variables
The bipolar disorder cohort comprised patients from all 14 NHS
Scotland health boards (see Supplementary Table 1 available at
https://doi.org/10.1192/bjp.2019.16). Because of very small numbers
of patients for three island-based health boards (Orkney, Shetland
and Western Isles), these three were combined for all analyses/
tables, both for ease of interpretation and to minimise risk of identi-
fying individual patients.
Data on marital status and ethnicity were missing for large
numbers of individuals, as these fields are not consistently completed
at the time of clinic/hospital attendance. Two separate coding systems
for marital status were employed within and between data sets. To
maximise patients with available data, we recoded patients with the
first, more detailed system into the second, simpler system, i.e.
‘single’, ‘married or separated’, ‘widowed’ and ‘other’ (including
divorce, civil partnership). Ethnicity was recorded as ‘White’;
‘Asian’, ‘Black’, or ‘mixed race/other’. Because of small numbers in
some categories, we recoded ethnicity as ‘White’ and ‘other’.
SIMD scores provide an index of deprivation based on area-
based measures of income, employment, education, housing,
health, crime and geographical access.20 SIMD 2012 quintiles
were used here, where one corresponds to the most deprived
areas, and five to the most affluent.
Reported health board, marital status, SIMD quintile and even
ethnicity in some instances changed within and/or between years.
The modal value for each patient and year was therefore included
in analyses conducted by year and, for tables/analyses reporting
values across all years, the modal values across 2009–2016 were
employed.
Using SMR00, SMR01 and SMR04 records, we identified the
date and year when a diagnosis of bipolar disorder first appeared
in each patient’s records: this may not necessarily represent the
date of first diagnosis. Date of death, where applicable, was extracted
from NRS deaths records. These dates were used to exclude from
analyses patients whose first record of bipolar disorder was in or
after a given year of interest and/or whose year of death (if applic-
able) was in or before a year of interest.
Data availability and ethical approval
All authors had access to the study data via the National Services
Scotland National Safe Haven. Data are not publically available as
they contain potentially sensitive information. Applications for
data access can be made via the ISD (http://www.isdscotland.org/
Products-and-Services/eDRIS/Data-for-Research/). The study was
facilitated by eData Research and Innovation Service (eDRIS)
under National Services Scotland’s favourable ethical opinion from
the East of Scotland NHS Research Ethics Service.
Results
Most common forms of treatment
Demographic characteristics (where available) are presented for all
treated patients with bipolar disorder in Supplementary Table 1, for
each (non-mutually exclusive) drug category. Table 1 presents the
ten most frequent combinations of drug types received by patients
across the period of interest (2009–2016). Of the 23 135 individuals
in the bipolar disorder cohort, 20 796 (89.89%)met criteria for being
treated for at least 1 year from 2009 to 2016. The most common
form of treatment collapsing across all years of interest was anti-
depressant monotherapy (24.96%), followed by antipsychotic
monotherapy (12.94%). Lithium monotherapy was the fifth most
common form of treatment, with only 5.90% of treated patients
receiving this as their modal treatment across the period 2009–2016.
The top ten most common forms of treatment separately for
each year are displayed in Supplementary Table 2. The pattern
was very similar to that for all years combined, with around 30–
40% of patients receiving either antidepressant monotherapy or
antipsychotic monotherapy as their modal form of treatment.
However, the proportion receiving antidepressant or lithiummono-
therapy declined gradually from 2009 to 2016.
Supplementary Table 3 shows the proportion of patients
receiving monotherapy (i.e. a single drug category), polypharmacy
of two distinct drug categories and polypharmacy of three or more
drug categories in each year of interest. This table highlights that a
slight decline in the proportion of patients receiving one or two
categories of medication from 2009–2016 was countered by an
Table 1 Ten most common forms of drug treatment among bipolar
disorder cohort, 2009–2016
Rank Drug combination Na %a
1 Antidepressant 5191 24.96
2 Antipsychotic 2690 12.94
3 Hypnotic/anxiolytic 1436 6.91
4 Antidepressant and antipsychotic 1287 6.19
5 Lithium 1226 5.90
6 Anti-epileptic 797 3.83
7 Valproate 755 3.63
8 Antipsychotic and valproate 635 3.05
9 Antidepressant and hypnotic/anxiolytic 605 2.91
10 Antidepressant, antipsychotic and hypnotic/
anxiolytic
552 2.65
Other All other combinations 5622 27.03
Total 20 796 100.00
a. N and % are for modal drug combinations per patient, across all included years, as a
percentage of all individuals in the bipolar disorder cohort who were treated in at least
one year from 2009 to 2016.
Prescribing for bipolar disorder in Scotland between 2009 and 2016
3
overall increase in patients prescribed three categories of medica-
tion. Trends in polypharmacy were then examined separately for
combinations including and not including lithium. The propor-
tion of patients prescribed combinations including lithium fell
slightly from 14.08 to 11.94%, whereas the proportion prescribed
combinations not including lithium increased from 27.05 to
31.34%.
Trends in prescriptions of different drug categories by
year
The proportion of treated patients receiving each of the six categor-
ies of medication (whether alone or in combination with other drug
categories) in each year from 2009 to 2016 is displayed in Fig. 1.
There was a steady increase in the percentage of patients treated
with antipsychotics (from 45.77 to 51.10%) and anti-epileptics
(from 15.20 to 23.24%), alongside a decline in the percentage receiv-
ing lithium prescriptions (from 25.98 to 21.95%). The overall per-
centage treated with antidepressants, hypnotics/anxiolytics and
valproate remained relatively stable over time.
We were also interested in examining whether prescribing of val-
proate has declined in women of childbearing age over the 2009–2016
period, in light of guidance highlighting the risks associated with fetal
exposure. Figure 2 shows an overall decline in prescriptions of valpro-
ate amongwomen of childbearing age, whereas the proportion of men
in the same age range prescribed valproate increased.
To examine change in the odds of prescriptions of each drug cat-
egory across the years of interest, adjusted for available sociodemo-
graphic characteristics, we used random effects logistic models with
standard errors clustered by patient. As data on sociodemographic
variables such as ethnicity and marital status were missing for large
numbers of patients, the models summarised in Table 2 adjusted
only for age and sex to maximise numbers (n = 20 300). Further
models additionally adjusted for SIMD score, ethnicity, marital
status and health board among the subset of patients with data on
these covariates (n = 9322), and are presented in Supplementary
Table 4. Multivariable random effects logistic models were employed
as we were interested in examining the influence of time-invariant
sociodemographic predictors (sex, ethnicity) on binary outcomes.
As patients often showed little variability in predictors and outcomes
across years of interest, it was not appropriate to use patients as their
own controls as in fixed effects models.21
The odds of being prescribed antipsychotics, valproate and
anti-epileptics all increased with each advancing year from
2009–2016 (Table 2); whereas the odds of treatment with
lithium declined with increasing year (odds ratio 0.83; 95% CI
0.82–0.85). Increases in year were not reliably associated with pre-
scriptions of antidepressants or of hypnotics/anxiolytics. In the
fully adjusted models (Supplementary Table 4), odds ratios were
slightly attenuated, but the significance and direction of results
were unchanged.
Overall, odds of receiving valproate increased over the years of
interest in both partially and fully adjusted models (partially
adjusted: odds ratio 1.09; 95% CI 1.07, 1.12; fully adjusted: odds
ratio 1.09; 95% CI 1.06, 1.12). However, as we were interested in
whether different trends were observed in women of childbearing
age compared with men of a similar age, the model was repeated
for valproate including a sex × year interaction term for individuals
aged 18–50 years. Among the 8898 individuals included in this ana-
lysis (adjusted for age and sex), the interaction was significant (odds
ratio 0.88; 95% CI 0.82–0.93; P < 0.001) and so stratified analyses
examined trends in women and men in the 18–50 year age range sep-
arately, adjusted for age. For men (n = 3407), each advancing year
from 2009 to 2016 was associated with increased odds of being
treated with valproate (odds ratio 1.11; 95% CI 1.04–1.18; P =
0.001); whereas for women of the same age range (n = 5491), each
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Fig. 1 Trends in the proportion of patients with bipolar disorder treated with eachmedication category across each year from 2009–2016. Data
for each year include patients whose first Scottish Morbidity Record of bipolar disorder occurs before the year of interest and whose date of
death (if applicable) occurs after the year of interest.
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year was associated with a decrease in odds of receiving valproate
(odds ratio 0.93; 95% CI 0.90–0.97; P < 0.001).
Discussion
We sought to use large-scale, national-level routine health data in
Scotland to investigate trends in prescribing for bipolar disorder
between the years 2009–2016. Our findings demonstrate the feasi-
bility of a routine data linkage approach and are of considerable
clinical interest in light of treatment guidelines for bipolar disorder.
It is notable that antidepressant monotherapy was the most
common form of treatment across all years, occurring in almost
one in four patients with bipolar disorder. This is an area for
concern because most treatment guidelines for bipolar disorder,
including those from NICE in 2006 and 2014, caution against the
use of antidepressants without mood stabiliser cover in bipolar dis-
order because of the risk of mood destabilisation and the potential to
precipitate hypomania or mania.3,4 Although there is evidence to
suggest antidepressants alongside mood stabilisers or antipsychotics
are not associated with more bipolar disorder-related hospital read-
missions,22,23 heightened risk of mania in patients with bipolar dis-
order treated with antidepressants as monotherapy has been clearly
documented in large samples.23
The percentage of patients with bipolar disorder receiving
lithium declined from 26% in 2009 to 22% in 2016, and less than
6% of patients with bipolar disorder were on lithium monotherapy
during this time. This low use of lithium and the trend towards
decreasing lithium use is in contrast with the most recent NICE
guidelines which encourage the first-line use of lithium and
indeed state that all patients with bipolar disorder should be
informed that lithium is the most effective long-term treatment.3
Clearly, the use of lithium in bipolar disorder can be complex
(and not all patients will be suitable candidates), but overall these
figures highlight a significant deviation between recommended
treatment and clinical practice. Of note, recent data from England
highlighted poor adherence to lithium monitoring guidelines by
practitioners,24 further suggesting a need to improve competencies
around lithium use. In contrast to the pattern for less year-on-year
lithium prescribing, we found that the odds of being prescribed
antipsychotics, valproate and anti-epileptics increased with each
year between 2009 and 2016.
It is likely that these trends in prescribing for bipolar disorder in
Scotland are the result of a wide range of factors. Changes tomedical
training may have resulted in younger cohorts of psychiatrists being
less likely to initiate lithium therapy. The pharmaceutical industry
has also successfully promoted the use of alternatives. Other influ-
ences include the demise of traditional lithium clinics and the loss
of Quality and Outcomes Framework incentives for lithium moni-
toring within primary care.25
We identified high rates of polypharmacy overall. In 2016,
almost 26% of patients were treated concurrently with two classes
of psychotropic medications and over 17% were treated with three
or more (Supplementary Table 3). The proportion of patients pre-
scribed three or more classes increased overall (from 15 to 17%)
between 2009 and 2016: the increase in polypharmacy appears to
be most evident in drug combinations (of at least two drug categor-
ies) not including lithium, which increased gradually from 27 to
31% of the cohort, whereas polypharmacy including lithium fell
(Supplementary Table 3). These trends suggest the increase in poly-
pharmacy is linked to the declining use of lithium. Although many
patients with bipolar disorder will require more than one class of
medication (e.g. a mood stabiliser in combination with an anti-
psychotic), we suggest that the trend over time for a greater propor-
tion of patients taking multiple classes of psychotropic medications is
a major concern. This is particularly relevant given the high rate of
cardiometabolic comorbidity observed in bipolar disorder.26
Despite previously being recommended as a first-line treatment
option, valproate is not currently recommended for use in women of
childbearing potential due to risks associated with fetal exposure.3,4
We found that the overall proportion of women prescribed valpro-
ate fell over time, likely reflecting better adherence to treatment
guidelines and greater clinical awareness of potential risks.27
An important limitation in this study is that classification of
individuals into the bipolar disorder cohort relied on the accuracy
of the ICD code diagnoses recorded by healthcare professionals
into electronic health records. Such records may be subject to
administrative and diagnostic error, or early diagnoses may later
be altered. However, a recent meta-analysis found the positive pre-
dictive value for bipolar disorder based on administrative data was
moderately high at around 75%.28
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A further issue is that the nature of the routine data employed
does not permit identification of which patients are no longer regis-
tered with the NHS in Scotland and whomay be receiving treatment
or have died elsewhere. We were unable to determine the propor-
tion of patients with bipolar disorder in Scotland who are not
treated in each year of interest. Inconsistent recording of sociode-
mographic data (e.g. marital status, ethnicity) also meant that
these variables might not have been adequately controlled for.
We took the conservative step of excluding from analyses the
small number of patients (n = 126) with ICD-9/-10 codes typically
considered to reflect either bipolar disorder type II or other/unspeci-
fied bipolar disorder.29 The findings are therefore not relevant to pre-
scribing patterns for bipolar disorder type II. In cohorts with larger
numbers and/ormore reliable distinction of bipolar disorder subtypes,
it will be of interest to compare trends across subtypes and with dis-
orders with overlapping symptoms such as schizoaffective disorder.
Importantly, bipolar disorder type II is more often treated with anti-
depressants and less often with lithium compared with bipolar dis-
order type I. Exclusion of these participants here means that the
observed trends towards decline in lithium and high use of antidepres-
sants is unlikely to be driven by the bipolar disorder II subtype. Despite
these limitations, this study demonstrates the feasibility of using
Scotland’s data linkage infrastructure to examine prescribing trends
at a nationwide level.
Definitions of treated and polypharmacy vary widely between
studies.14 A strength of this study is that relatively conservative criteria
were used for each. Patients were defined as treated only in the pres-
ence of evidence of consistent use of a given drug category over at
least 3months; polypharmacy of drug categories was defined using evi-
dence of consistent prescription of multiple drug categories on the
same date. These definitions mean the observed trends likely reflect
patients’ established forms of treatment and are unlikely to be biased
by brief trials of medications or by transitions between medications.
Although this study focused on data from NHS Scotland, these
trends are likely to reflect practice across the UK and internation-
ally. Bipolar disorder is a complex and highlymorbidmood disorder
but it can be managed effectively by combining medication with
psychosocial approaches. Our findings suggest that most patients
with bipolar disorder in Scotland are missing out on optimal treat-
ments (such as lithium) and that many are receiving treatments
(such as antidepressant monotherapy) that are at best ineffective
and, at worse, detrimental for long-term outcome.
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